MitrAssist Lifesciences Ltd, a Shanghai-based innovator in cardiovascular device manufacturing, has reportedly raised nearly USD 100 million in a Series C financing round. The funding was led by Centurium Capital and 6 Dimensions Capital, with contributions from Shanghai Jiading Industrial Development Group, Shanghai Jiajia Group, Hefei Haiheng Holdings, Hefei Industrial Investment, Hefei Binhu Science and Technology Innovation Investment, and Anyuan Fund.
Funding Allocation and Strategic Growth
The proceeds from this significant funding round will be directed towards the regulatory clinical study and market access for MitrAssist’s interventional mitral valve membrane replacement product and its polymer intervention aortic valve replacement product (Polymer TAVR). Additionally, the funds will support clinical trials for other products in the pipeline, the marketing of non-invasive heart failure monitoring equipment and coronary drug balloons, as well as domestic and international product promotion and application.
Global Presence and Product Innovation
Founded in 2017, MitrAssist has established R&D centers in China, Israel, and Germany, and a marketing team in the United States. The company’s Mitrafix, a percutaneous mitral valve replacement product, is noted as the first of its kind in China and has obtained fast-track status. This recognition underscores MitrAssist’s commitment to innovation in cardiovascular care. Furthermore, its non-invasive heart failure management device, ReDS Pro, which is already available in the US, Europe, India, and Japan, received marketing approval in China this year, expanding its global footprint.-Fineline Info & Tech
